Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Apr;143(4):407-412.
doi: 10.1111/ane.13389. Epub 2021 Jan 15.

Levetiracetam as first-line monotherapy for Idiopathic Generalized Epilepsy in women

Alejandro Ballvé  1 , Javier Salas-Puig  1 , Manuel Quintana  1   2   3 , Daniel Campos  1 , Arnau Llauradó  1 , Miquel Raspall  1   4 , Elena Fonseca  1   2   3 , Laura Abraira  1   2   3 , Estevo Santamarina  1   2   3 , Manuel Toledo  1   2   3
Affiliations
Observational Study

Levetiracetam as first-line monotherapy for Idiopathic Generalized Epilepsy in women

Alejandro Ballvé et al. Acta Neurol Scand. 2021 Apr.

Abstract

Background: Levetiracetam (LEV) is effective in Idiopathic Generalized Epilepsy (IGE) and seems to be a good alternative to valproic acid in women of childbearing age. However, there is lack of approval for this indication as monotherapy. The aim of this study is to assess the efficacy of LEV as a first-line therapy in this population.

Methods: The study is a descriptive analysis of women aged between 16 and 45 years old diagnosed with IGE and treated with LEV as first-line monotherapy. Minimum follow-up was 24 months.

Results: 26 women. Mean age: 25.4 years (17-43). 14 Juvenile Myoclonic Epilepsy; 8 Tonic-Clonic Seizures Alone; 4 Juvenile Absence. Mean follow-up: 68.3 months (24-120). 11 patients (40.7%) continued to take LEV as monotherapy, of which 10 were seizure-free, and three (11.5%) continue to be seizure-free after withdrawing LEV. 12 patients (46.2%) required a change of treatment: 25% (3/12) due to lack of efficacy, 42% (5/12) due to adverse effects and 33% (4/12) due to both. Irritability was the most frequent adverse effect. At the last assessment, three patients (11.5%) continued to have seizures despite polytherapy. Estimated retention rates were 78.1% at one year (SE 7.3%) and 51% at 5 years (SE 9.8%). Estimated median retention time is 72 months (CI 95%: 50.9-93.1).

Conclusion: LEV could be an effective drug as first-line treatment for IGE in women of childbearing potential. The adverse effects are its main limitation. Comparative studies are needed in order to establish it for this indication.

Keywords: childbearing; epilepsy; genetic generalized epilepsy; idiopathic generalized; levetiracetam; women.

PubMed Disclaimer

References

REFERENCES

    1. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1016-1026.
    1. Calleja S, Salas-Puig J, Ribacoba R, Lahoz CH. Evolution of juvenile myoclonic epilepsy treated from the outset with sodium valproate. Seizure. 2001;10:424-427.
    1. Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs I: treatment of new-onset epilepsy. Epilepsy Curr. 2018;18:260-268.
    1. Krauss GL, Betts T, Abou-Khalil B, Bergey G, Yarrow H, Miller A. Levetiracetam treatment of idiopathic generalised epilepsy. Seizure. 2003;12:617-620.
    1. Cerulli Irelli E, Morano A, Cocchi E, et al. Doing without valproate in women of childbearing potential with idiopathic generalized epilepsy: implications on seizure outcome. Epilepsia. 2020;61:107-114.

Publication types

Supplementary concepts

LinkOut - more resources